Home / Business and Economy / Ozempic Faces Generic Rivals in Canada
Ozempic Faces Generic Rivals in Canada
29 Apr
Summary
- Generic Ozempic versions launched in India, impacting prices.
- Sandoz plans generic Ozempic launch in Canada by June.
- Health Canada reviews eight other generic semaglutide applications.
Novo Nordisk's popular diabetes drug Ozempic is facing increasing competition from lower-cost generic versions. Following the expiry of certain patent protections, India became the first major market to introduce copycat semaglutide in March, leading Novo Nordisk to reduce prices there.
Now, the focus shifts to Canada, where Swiss generic drugmaker Sandoz has announced plans to launch its generic version of Ozempic by June 2026. This move positions Sandoz among the first wave of companies aiming to market generic peptides of the GLP-1 therapy.
Health Canada is actively reviewing eight other applications for generic semaglutide from different pharmaceutical companies. The agency anticipates making further decisions in the upcoming weeks and months.
In Canada, generic medications typically offer substantial savings, often ranging from 45% to 90% cheaper than their brand-name counterparts. This trend is expected to significantly impact Ozempic's market share, especially as Eli Lilly's rival GLP-1 drugs also continue to gain traction.
